



Vitamin D Status in COVID-19 Patients Versus Non-COVID-19 Individuals and Its Association with the Severity of Infection

Yasamin Khosravani-Nezhad ¹, Mehrangiz Zangeneh ^{1,*}, Masoomeh Mesgarian ¹, Seyed Davar Siadat ², Mohammad Bagheri-Mansouri³ and Zahra Vosoughi³

¹Department of Infectious Diseases, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran

²Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran

³Treata Hospital, Tehran, Iran

*Corresponding author: Department of Infectious Diseases, Tehran Medical Sciences Branch, Islamic Azad University, 19395/1495, Tehran, Iran. Tel: +98-2122006660-7, Email: zangeneh4@yahoo.com

Received 2022 March 30; Revised 2022 July 15; Accepted 2022 July 19.

Abstract

Background: The recent severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in millions of confirmed cases of infection and death. Vitamin D modulates the adaptive and innate immune systems; therefore, vitamin D deficiency may be related to the severity of coronavirus disease 2019 (COVID-19).

Methods: This study was performed on 122 COVID-19 patients and 122 non-COVID-19 individuals to determine the possible relationship between vitamin D deficiency and COVID-19 severity. Besides, the relationship between vitamin D status and the severity of disease was investigated in 49 patients without an underlying disease. The COVID-19 severity was defined based on O₂ saturation, respiratory rate, and pulmonary involvement. Also, vitamin D status was defined as follows: Vitamin D deficiency (< 30 ng/mL) and vitamin D sufficiency (≥ 30 ng/mL).

Results: The mean age of 122 COVID-19 patients, including 71 (58.2%) male patients and 51 (41.8%) women patients, was 59 ± 16 years in this study, while the mean age of the controls, including 61 male participants and 61 female participants, was 48 ± 13 years ($P < 0.05$). The mean vitamin D level was 34.14 ± 1 ng/mL in the patients and 32.94 ± 1 ng/mL in the controls ($P = 0.872$). However, there was no significant correlation in none of all the 122 patients and 49 patients without an underlying disease ($P = 0.074$, $P = 0.261$).

Conclusions: Based on the present findings, the correlation between vitamin D status and COVID-19 severity was not significant neither in 122 patients, and nor in 49 patients without an underlying disease.

Keywords: COVID-19, Severity, Vitamin D, Deficiency

1. Background

In early December 2019, the first case of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was discovered in Wuhan, China. Soon, the coronavirus disease 2019 (COVID-19) pandemic was declared by the World Health Organization (WHO) throughout the world. Until October 2021, the WHO reported about 233 million confirmed cases of COVID-19 and 4.7 million deaths, with a mortality rate of 2.1% (1). Mainly, SARS-CoV-2 is transmitted by inhalation of droplets. The average incubation period of this disease is two weeks (2, 3).

The pulmonary involvement of COVID-19 patients ranges from a normal pattern to complete pulmonary involvement (4). Nonetheless, the most common CT scan finding in COVID-19 patients is bilateral subpleural ground-glass opacity (GGO) (5). The clinical pattern of SARS-CoV-2 infection may range from asymptomatic infec-

tion to acute respiratory distress syndrome (ARDS) and multi-organ dysfunction (6, 7). The therapeutic options for this disease include antivirals, immunomodulators, and corticosteroids; however, no specific drug has been yet approved for COVID-19 treatment (8).

There are several studies reporting the role of vitamin D in regulating the immune system and reducing the respiratory tract infection severity (9-12). Generally, the primary source of vitamin D for humans is sunlight. The ultraviolet-B (290 - 315 nm) portion of solar radiation converts 7-dehydrocholesterol to pre-vitamin D₃ in the skin, which is then transformed to vitamin D₃ (13). Vitamin D receptors are found not only in the classic target tissues of vitamin D, such as the bone, gut, and kidney tissues, but also in other organs, including the lungs (14).

1,25-Dihydroxyvitamin D (1,25(OH)₂D) is the active metabolite of vitamin D, affecting both adaptive and in-

nate immune systems (15). As an active hormone, it participates in the regulation of genes, which encode some proteins required for the first wall barrier (16). In innate immunity, a sufficient serum circulation of $1,25(\text{OH})_2\text{D}$ can produce cathelicidins and defensins with antimicrobial activities (17). Vitamin D also has direct antiviral effects, especially against enveloped viruses. Besides, cell culture studies suggest the antiviral role of vitamin D against enveloped viruses by upregulating antimicrobial peptides, including LL-37 (18).

The coronavirus (CoV) envelope protein is a small, integral membrane protein that participates in several parts of the virus life cycle, such as production, maturation, and pathogenesis. It has been shown that recombinant CoVs without envelope-producing genes can significantly reduce the viral titers (19). According to reports, vitamin D status varies around the world. In a narrative review by Lips in 2007, vitamin D deficiency was common in the Middle East, Southern Europe, India, China, and Japan, while it was less common in Northern Europe and Southeast Asia (20). In 2016, Cashman et al. found that 13.1% of Europeans (55,844) had serum $25(\text{OH})\text{D}$ levels below 30 nmol/L (21).

From 1988 to 2006, the prevalence of serum $25\text{-Hydroxy vitamin D}_3$ ($25(\text{OH})\text{D}$) below 30 nmol/L increased from 5% to 10% in North America. The highest prevalence of serum $25(\text{OH})\text{D}$ level < 50 nmol/L was reported in Argentina and Chile (22). Based on the WHO reports, Argentina and Chile are among the first 20 countries with the highest number of confirmed COVID-19 cases.

Although there is not enough evidence regarding the relationship between COVID-19 severity and vitamin D deficiency (23-25), some researchers have reported a relationship (26-28). In this regard, Hastie et al. examined the vitamin D status and COVID-19 in the UK Biobank. However, they could not provide any evidence to support the association of $25(\text{OH})\text{D}$ status with COVID-19 susceptibility (29). In another study by Baktash et al. the outcomes of COVID-19 were studied in older adults with vitamin D deficiency, and the results confirmed the correlation between COVID-19 severity and vitamin D deficiency (30). Overall, there are some contradictory findings on whether COVID-19 susceptibility and severity depend on vitamin D status. In independent studies by Moradzadeh et al. and Sadinia et al. the prevalence of vitamin D deficiency was high in most parts of Iran and the Middle East (31, 32).

2. Objectives

Considering the high prevalence of vitamin D deficiency in Iran and the existing evidence of its possible association with the current critical status of COVID-19, this study aimed to examine the level of vitamin D and determine its association with the severity of infection.

3. Methods

This retrospective, cross-sectional study was performed on 122 patients with symptomatic COVID-19 and 49 COVID-19 positive patients without an underlying disease, hospitalized in Amir-al-Momenin Hospital, affiliated to Islamic Azad University of Tehran, Iran, from April 2020 to May 2020, as well as 122 non-COVID-19 individuals as a control group, who were examined for vitamin D status. The patients were positive for COVID-19, based on reverse transcriptase-polymerase chain reaction (RT-PCR) of nasopharyngeal and pharyngeal swab specimens. The CT scans, laboratory tests, and clinical examinations were performed for each patient.

The vitamin D status was measured based on the serum $25\text{-Hydroxy vitamin D}_3$ ($25(\text{OH})\text{D}$) level in each patient by electrochemiluminescence (ECL) method. Vitamin D deficiency was defined as a $25(\text{OH})\text{D}$ level below 30 ng/mL in this study. The vitamin D level was measured on the first day of receiving inpatient services and before medication use. None of the patients used vitamin D supplements. The CT scans of all patients were acquired in the supine position without an intravenous contrast; all images were acquired based on standard scanning protocols. All CT scans were reviewed by the hospital radiologists. The pulmonary involvement was classified as follows: 0 (0% involvement), 1 (1-24% involvement), 2 (25-49% involvement), 3 (50-74% involvement), and 4 (75-100% involvement). This study was approved by the ethics committee of Islamic Azad University of Medical Sciences (IR.IAU.PS.REC.1399.036).

The severity of COVID-19 was categorized into four groups: Mild, moderate, severe, and critical. Mild infection was defined as a respiratory rate of 24 beats per minute (bpm) or less, O_2 saturation of 93% or higher on room air, and a normal chest CT scan (or < 25% pulmonary involvement). Moderate infection was defined as O_2 saturation of 90-93% on room air, a respiratory rate of 24-30 bpm, and chest CT scan involvement of 25-50%. Severe infection was defined as O_2 saturation of 90% or less on room air, a respiratory rate of 30 bpm or higher, and pulmonary involvement > 50%. Finally, critical cases were under ventilation or experienced septic shock, along with COVID-19 complication.

The demographic information, clinical characteristics, CT findings, and laboratory results of all patients were gathered in questionnaires from the patients' records. First, the vitamin D levels of all patients were compared with the controls, and then, the association of vitamin D level with the severity of disease was examined. Patients with underlying conditions, such as autoimmune disease, cancer, hypertension, diabetes, pulmonary disease, renal diseases, and cardiovascular disease, were excluded. A total of 49 patients remained in the study. The vitamin D

status of 49 patients was examined in relation to COVID-19 severity.

The collected data were entered in IBM® SPSS® Version 26.0. The frequencies and mean values of all variables were calculated and compared to obtain reliable results. SPSS was used to calculate the probability value (P-value). For comparing the means of each O₂ saturation, respiratory rate, and lung involvement percentage with vitamin D status, Kolomogrov-Smirnov test and independent *t*-test were used, and Spearman correlation of the amount of each variable and vitamin D status was also calculated. For comparing the severity of the disease with vitamin D status chi-square test was used and for comparing vitamin D status in the two groups, Mann-Whittney test was used. The Mann-Whittney test was also used for analyzing each O₂ saturation, respiratory rate, and lung involvement percentage with vitamin D status of 49 patients without underlying diseases. P-value less than 0.05 was considered statistically significant.

4. Results

The mean \pm SD age of 122 COVID-19 patients was 59 ± 16 years, and 71 (58.2%) patients were male. Overall, 77 (63%) patients were positive for COVID-19, based on RT-PCR using nasopharyngeal and pharyngeal swab specimens upon arrival, and the rest of the patients were positive in the second and third examinations. Also, the mean age of the controls, including 61 males, was 48 ± 13 years; the mean age of the patients was higher than that of the controls ($P < 0.05$). Based on the findings, the mean inpatient duration was 7 ± 4 days, and the mean duration of medication use was 9 ± 3 days. The mean vital signs were as follows: Pulse rate, 89.7 ± 15.3 bpm; O₂ saturation percentage, $89.4 \pm 8.9\%$; systolic blood pressure, 118.6 ± 16.65 mmHg; diastolic blood pressure, 73.2 ± 12.9 mmHg; respiratory rate, 19.4 ± 8.3 bpm, and temperature, $37.4 \pm 0.8^\circ\text{C}$ upon arrival.

The most common symptoms were dyspnea (78.7%), cough (77%), body temperature $> 38^\circ\text{C}$ (69.7%), malaise (65%), loss of appetite (61.5%), myalgia (62.3%), and chest pain (50.8%). The analysis of pulmonary involvement indicated the following results: Normal lungs in 2 (1.6%) cases; $< 25\%$ involvement in 22 (18.0%) cases; 25 - 49% involvement in 70 (57.4%) cases; 50 - 74% involvement in 25 (20.5%) cases; and $\geq 75\%$ lung involvement in 3 (2.5%) cases.

The mean vitamin D level was 34.14 ± 1 ng/mL (95% CI: 30.43 - 37.85) in the patients and 32.94 ± 1 ng/mL (95% CI: 30.13 to 35.74) in the controls. The patients had higher vitamin D levels compared to the controls; however, the difference was not significant ($P = 0.872$). The vitamin D level of 60 (49.2%) patients was deficient, and half of the controls (50%) were deficient in vitamin D. Also, 58 (47.5%) patients were mildly infected, 41 (33.6%) patients were moderately

infected, and 23 (18.9%) patients were severely infected. In 49 patients without an underlying disease, the mean vitamin D level was 32.85 ± 19 ng/mL (95% CI: 27.29 - 38.41). Overall, 27 (55.1%) patients were mildly infected, 16 (32.7%) patients were moderately infected, and 6 (12.2%) patients were severely infected.

Comparison of vitamin D level and O₂ saturation showed that patients with O₂ saturation $> 93\%$ were mostly vitamin D sufficient (55.2%); these cases were considered mild. Also, 50% of patients with O₂ saturation $< 90\%$ were vitamin D deficient, with a two-tailed P-value of 0.324; therefore, the correlation was not significant. Moreover, comparison of vitamin D status and respiratory rate indicated that 50% of patients with a respiratory rate > 30 bpm had vitamin D deficiency; this correlation was not significant, with a two-tailed P-value of 0.162. Moreover, comparison of vitamin D status and percentage of pulmonary involvement revealed that patients with 25% pulmonary involvement or more had vitamin D levels below 30 ng/mL, however, the result was not significant (two-tailed P-value = 0.074). Overall, the results showed that the severity of disease was not related to the vitamin D status of the patients; in other words, a higher severity of COVID-19 was not associated with a lower vitamin D level; the P-value was 0.125, and the correlation was not significant (Table 1).

Moreover, 49 patients without an underlying disease were examined in this study. The results indicated that patients with lower percentages of O₂ saturation were mostly vitamin D deficient; however, the distribution was non-parametric, and the P-value (0.127) was not significant. Analysis of respiratory rate and pulmonary involvement percentage in relation to the vitamin D status showed no significant relationship ($P > 0.05$). Finally, analysis of the relationship between the severity of disease and vitamin D status showed no significant correlation in patients without an underlying disease ($P > 0.05$) (Table 2).

5. Discussion

In the present study, the vitamin D status was not significantly different between 122 patients with COVID-19 and the controls ($P > 0.05$). The correlation between vitamin D level and disease severity was also not significant in 122 patients ($P > 0.05$), and in 49 patients without an underlying disease, the correlation was not significant ($P > 0.05$). The insignificant correlation in this study suggests that in small scale of individuals vitamin D deficiency was not related to neither COVID-19, nor its severity. However, in larger community the results could be different. Nonetheless, the Spearman's Rho correlation demonstrated that respiratory rate and lung involvement percentage correlation with vitamin D status was more meaningful in 122 patients than those without underlying dis-

Table 1. The Relationship Between Vitamin D Status and COVID-19 in All 122 Patients ^a

Status	Vitamin D Level			P Value	Spearman's Rho
	25(OH)D < 30 (% Within Vit D)	30 ≤ 25(OH)D (% Within Vit D)	Total (% Within Total)		
O₂ saturation (%)				0.324	0.051
< 90	21 (50)	21 (50)	42 (34.4)		
90 - 93	17 (54.8)	14 (45.2)	31 (25.4)		
93 <	22 (44.8)	27 (55.2)	49 (40.2)		
Total	60	62	122		
Respiratory rate (times/min)				0.162	-0.140
< 24	52 (48.1)	56 (51.9)	108 (89.3)		
24 - 30	5 (55.6)	4 (44.4)	9 (7.4)		
30 <	2 (50)	2 (50)	4 (3.3)		
Total	59	62	121		
Lung involvement percentage (%)				0.074	-0.181
0	1 (50)	1 (50)	2 (1.6)		
1 - 24	7 (31.8)	15 (68.2)	22 (18.0)		
25 - 49	35 (50)	35 (50)	70 (57.4)		
50 - 74	15 (60)	10 (40)	25 (20.5)		
75 - 100	2 (66.6)	1 (43.4)	3 (2.5)		
Total	60	62	122		
Severity				0.125	-
Mild	23 (39.7)	35 (60.3)	58 (47.5)		
Moderate	23 (56)	18 (44)	41 (33.6)		
Severe	14 (60.8)	9 (39.2)	23 (18.9)		
Total	60	62	122		

Abbreviation: Vit D, vitamin D.

^a Vitamin D status is in ng/mL.

ease, this could show that some underlying diseases would affect the serum vitamin D level, which might increase the respiratory rate and lung involvement. In meta-analyses, several researchers have examined the antiviral role of vitamin D sufficiency in the human body and its alleviating role in acute respiratory tract infections. The serum vitamin D level can predict the severity of the recent SARS-CoV-2 infection (18, 33, 34). Vitamin D deficiency may also suppress dipeptidyl peptidase-4 (DDP4/CD26) as one of the adhesion molecules for the Middle East respiratory syndrome (MERS)-CoV and COVID-19 in the human body cells (35, 36).

In the present study, the patients' vitamin D status and O₂ saturation were compared, similar to a study by Franco et al. and another study by Choudhary and Gupta on children under five years. Some of the patients with adequate vitamin D levels had less severe infections. However, in

the current study, there was no significant correlation between vitamin D status and O₂ saturation, similar to the study by Choudhary and Gupta, despite the age differences of participants in these two studies. The present results did not indicate a higher respiratory rate associated with vitamin D deficiency. In the study by Franco et al. the risk and severity of ARDS and pneumonia were higher in vitamin D-deficient patients; it should be noted that Franco et al. studied patients with chronic obstructive pulmonary disease (COPD) (37, 38).

In this study, the association of vitamin D deficiency with pulmonary involvement was examined in COVID-19 patients. Based on the results, patients with 25% pulmonary involvement or more had vitamin D levels below 30 ng/mL compared to those with vitamin D levels of 30 ng/mL or higher. The current results showed a non-significant relationship between pulmonary involvement

Table 2. The Relationship Between Vitamin D Status and COVID-19 on 49 Patients ^{a, b}

Status	Vitamin D Level			P Value	Spearman's Rho
	25(OH)D < 30 (% Within Vit D)	30 ≤ 25(OH)D (% Within Vit D)	Total (% Within Total)		
O₂ saturation (%)				0.127	0.183
< 90	6 (54.4)	5 (45.5)	11 (22.5)		
90 - 93	11 (64.7)	6 (35.3)	17 (34.7)		
93 <	8 (38)	13 (62)	21 (42.8)		
Total	25	24	49		
Respiratory rate (times/min)				0.408	-0.114
< 24	25 (54.3)	21 (45.7)	46 (0)		
24 - 30	0 (0)	3 (100)	3 (7.4)		
30 <	0 (0)	0 (0)	0 (0)		
Total	25	24	49		
Lung involvement percentage (%)				0.714	-0.109
0	1 (50)	1 (50)	2 (4)		
1 - 24	3 (30)	7 (70)	10 (20.4)		
25 - 49	17 (58.6)	12 (41.4)	29 (59.2)		
50 - 74	2 (40)	3 (60)	5 (10.2)		
75 - 100	2 (66.6)	1 (43.4)	3 (6.2)		
Total	25	24	49		
Severity				0.261	-
Mild	11 (40.7)	16 (59.3)	27 (55.2)		
Moderate	11 (68.7)	5 (31.3)	16 (32.6)		
Severe	3 (50)	3 (50)	6 (12.2)		
Total	25	24	49		

Abbreviation: Vit D, vitamin D.

^a Values are expressed as No. (%).^b Vitamin D status is in ng/mL.

and vitamin D status, versus a study by Zosky et al. on vitamin D deficiency and its effects on the pulmonary function and changes in the lung structure in mice samples. Zosky et al. found that vitamin D deficiency decreases lung volume and function, however the whole study explains the association between obstructive lung disease and vitamin D status (39).

The results of the present study indicated the insignificant effects of vitamin D deficiency on the COVID-19 severity. We need to show that patients with moderate and severe diseases have lower vitamin D levels than mild cases. There are several studies showing that vitamin D deficiency can potentially increase the severity of SARS-CoV-2 infection. In a study by Brenner et al. in Germany, vitamin D deficiency and insufficiency contributed to a COVID-19 mortality rate of 41% (40). In another similar study by D'Avolio et

al. in Switzerland, the vitamin D level of PCR-positive SARS-CoV-2 patients, aged 70 years or above, was deficient (median, 11.1 ng/mL); however, the age range of participants in their study was different from ours (41).

Although there are studies similar to the one by Panagiotou et al. rejecting a correlation between vitamin D status and mortality, our study focused on the severity of disease rather than mortality. Panagiotou et al. studied 134 hospitalized COVID-19 patients and showed that only 19% of the participants had sufficient vitamin D levels (42). Moreover, Hastie et al. examined the association between vitamin D level and COVID-19 after removing participants with potential cofounders similar to 49 patients of ours without underlying diseases, and found no significant correlation; however, the correlation between vitamin D status and COVID-19 severity was unclear in their study (29).

In conclusion, vitamin D deficiency (25(OH)D level < 30 ng/mL) was not associated with COVID-19 severity in all patients who participated in this study. As well as the patients without an underlying disease. On the other hand, the analysis of disease severity and vitamin D status of patients without an underlying disease demonstrated that vitamin D sufficiency was more common in patients with a mild disease compared to those with a moderate disease. However, among severely infected cases, the number of patients was not significantly different in relation to the vitamin D status ($P > 0.05$).

5.1. Conclusions

The present study did not find a significant relationship between the vitamin D status and the severity of COVID-19 in patients with/without an underlying disease. For investigating this correlation, it is important to exclude the underlying diseases. We know well that evidence is against our findings, therefore, for more accurate results, a larger sample size and further case-control studies are required. Besides, use of vitamin D supplementation for COVID-19 patients with vitamin D deficiency seems beneficial; therefore, we highly recommend this supplementation for all patients with vitamin D deficiency.

Acknowledgments

We appreciate all the patients who consented to their reported information and were involved in this study.

Footnotes

Authors' Contribution: Study concept, design and supervision, M.Z., and M.M.; Acquisition of the data, Y.Kh., and M.Z.; Interpretation and statistical analysis of the data, Y.Kh.; Critical revision of the manuscript for important intellectual content, M.Z., M.M., and S.D.S.; Drafting of the manuscript, Y.Kh., and M.Z.; Technical and material support, M.B., and Z.V.

Conflict of Interests: We declare no conflicts of interest.

Data Reproducibility: All the information used in this manuscript is available in the patients' files at the center.

Ethical Approval: This study was approved by the ethics committee of Islamic Azad University of Medical Sciences (IR.IAU.PS.REC.1399.036; link: ethics.research.ac.ir/EthicsProposalViewEn.php?id130253).

Funding/Support: Any agency or organization did not fund this project.

Informed Consent: Written informed consent was obtained from the patients for publication of this article. A

copy of the written consent is available for review by editor-in-chief of this journal.

References

- World Health Organization. *Coronavirus disease (COVID-19)*. Geneva, Switzerland: World Health Organization; 2020. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
- Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment. *Influenza Other Respir Viruses*. 2020;**14**(4):474–5. doi: [10.1093/irv/12743](https://doi.org/10.1093/irv/12743). [PubMed: [32246886](https://pubmed.ncbi.nlm.nih.gov/32246886/)]. [PubMed Central: [PMC7228388](https://pubmed.ncbi.nlm.nih.gov/PMC7228388/)].
- Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 2020;**172**(9):577–82. doi: [10.7326/M20-0504](https://doi.org/10.7326/M20-0504). [PubMed: [32150748](https://pubmed.ncbi.nlm.nih.gov/32150748/)]. [PubMed Central: [PMC7081172](https://pubmed.ncbi.nlm.nih.gov/PMC7081172/)].
- Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020;**295**(3):200463. doi: [10.1148/radiol.2020200463](https://doi.org/10.1148/radiol.2020200463). [PubMed: [32077789](https://pubmed.ncbi.nlm.nih.gov/32077789/)]. [PubMed Central: [PMC7233369](https://pubmed.ncbi.nlm.nih.gov/PMC7233369/)].
- Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol*. 2020;**214**(5):1072–7. doi: [10.2214/AJR.20.22976](https://doi.org/10.2214/AJR.20.22976). [PubMed: [32125873](https://pubmed.ncbi.nlm.nih.gov/32125873/)].
- Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). *Indian J Pediatr*. 2020;**87**(4):281–6. doi: [10.1007/s12098-020-03263-6](https://doi.org/10.1007/s12098-020-03263-6). [PubMed: [32166607](https://pubmed.ncbi.nlm.nih.gov/32166607/)]. [PubMed Central: [PMC7090728](https://pubmed.ncbi.nlm.nih.gov/PMC7090728/)].
- Salehi S, Abedi A, Balakrishnan S, Gholamrezaezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *AJR Am J Roentgenol*. 2020;**215**(1):87–93. doi: [10.2214/AJR.20.23034](https://doi.org/10.2214/AJR.20.23034). [PubMed: [32174129](https://pubmed.ncbi.nlm.nih.gov/32174129/)].
- Bhimraj A, Morgan RL, Shumaker AH, Laverne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clin Infect Dis*. 2020;**ciaa478**. doi: [10.1093/cid/ciaa478](https://doi.org/10.1093/cid/ciaa478). [PubMed: [32338708](https://pubmed.ncbi.nlm.nih.gov/32338708/)]. [PubMed Central: [PMC7197612](https://pubmed.ncbi.nlm.nih.gov/PMC7197612/)].
- Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Kostenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. *Eur J Clin Nutr*. 2020;**74**(11):1498–513. doi: [10.1038/s41430-020-0558-y](https://doi.org/10.1038/s41430-020-0558-y). [PubMed: [31959942](https://pubmed.ncbi.nlm.nih.gov/31959942/)]. [PubMed Central: [PMC7091696](https://pubmed.ncbi.nlm.nih.gov/PMC7091696/)].
- Aranow C. Vitamin D and the immune system. *J Investig Med*. 2011;**59**(6):881–6. doi: [10.2310/JIM.0b013e31821b8755](https://doi.org/10.2310/JIM.0b013e31821b8755). [PubMed: [21527855](https://pubmed.ncbi.nlm.nih.gov/21527855/)]. [PubMed Central: [PMC3166406](https://pubmed.ncbi.nlm.nih.gov/PMC3166406/)].
- Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. *Curr Opin Pharmacol*. 2010;**10**(4):482–96. doi: [10.1016/j.coph.2010.04.001](https://doi.org/10.1016/j.coph.2010.04.001). [PubMed: [20427238](https://pubmed.ncbi.nlm.nih.gov/20427238/)].
- Bhutta ZA. Vitamin D reduces respiratory tract infections frequency. *J Pediatr*. 2017;**186**:209–12. doi: [10.1016/j.jpeds.2017.04.021](https://doi.org/10.1016/j.jpeds.2017.04.021). [PubMed: [28648275](https://pubmed.ncbi.nlm.nih.gov/28648275/)].
- Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. *J Clin Endocrinol Metab*. 1988;**67**(2):373–8. doi: [10.1210/jcem-67-2-373](https://doi.org/10.1210/jcem-67-2-373). [PubMed: [2839537](https://pubmed.ncbi.nlm.nih.gov/2839537/)].
- Bikle D. Nonclassic actions of vitamin D. *J Clin Endocrinol Metab*. 2009;**94**(1):26–34. doi: [10.1210/jc.2008-1454](https://doi.org/10.1210/jc.2008-1454). [PubMed: [18854395](https://pubmed.ncbi.nlm.nih.gov/18854395/)]. [PubMed Central: [PMC2630868](https://pubmed.ncbi.nlm.nih.gov/PMC2630868/)].
- Bikle DD. Chapter one - Vitamin D Regulation of Immune Function. In: Litwack G, editor. *Vitamins and the Immune System, Vitamins & Hormones*. **86**. London, UK: Academic Press; 2011. p. 1–21. doi: [10.1016/B978-0-12-386960-9.00001-0](https://doi.org/10.1016/B978-0-12-386960-9.00001-0).

16. Clairmont A, Tessman D, Stock A, Nicolai S, Stahl W, Sies H. Short communication: Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear vitamin D receptor. *Carcinogenesis*. 1996;**17**(6):1389–91. doi: [10.1093/carcin/17.6.1389](#). [PubMed: [8681462](#)].
17. Cederlund A, Gudmundsson GH, Agerberth B. Antimicrobial peptides important in innate immunity. *FEBS J*. 2011;**278**(20):3942–51. doi: [10.1111/j.1742-4658.2011.08302.x](#). [PubMed: [21848912](#)].
18. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. *J Clin Virol*. 2011;**50**(3):194–200. doi: [10.1016/j.jcv.2010.12.006](#). [PubMed: [21242105](#)]. [PubMed Central: [PMC3308600](#)].
19. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. *Virus J*. 2019;**16**(1):69. doi: [10.1186/s12985-019-1182-0](#). [PubMed: [31133031](#)]. [PubMed Central: [PMC6537279](#)].
20. Lips P. Vitamin D status and nutrition in Europe and Asia. *J Steroid Biochem Mol Biol*. 2007;**103**(3-5):620–5. doi: [10.1016/j.jsbmb.2006.12.076](#). [PubMed: [17287117](#)].
21. Cashman KD, Dowling KG, Skrabakova Z, Gonzalez-Gross M, Valtuena J, De Henauw S, et al. Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr*. 2016;**103**(4):1033–44. doi: [10.3945/ajcn.115.120873](#). [PubMed: [26864360](#)]. [PubMed Central: [PMC5527850](#)].
22. van Schoor N, Lips P. Chapter 59 - Worldwide Vitamin D Status. In: Hewison M, Bouillon R, Giovannucci E, Goltzman D, editors. *Vitamin D, Volume 2: Health, Disease and Therapeutics*. 2. 4 ed. London, UK: Academic Press; 2018. p. 15–40. doi: [10.1016/b978-0-12-809963-6.00059-6](#).
23. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. *J Infect Public Health*. 2020;**13**(10):1373–80. doi: [10.1016/j.jiph.2020.06.021](#). [PubMed: [32605780](#)]. [PubMed Central: [PMC7305922](#)].
24. Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS J*. 2020;**287**(17):3693–702. doi: [10.1111/febs.15495](#). [PubMed: [32700398](#)]. [PubMed Central: [PMC7404739](#)].
25. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res*. 2020;**32**(7):1195–8. doi: [10.1007/s40520-020-01570-8](#). [PubMed: [32377965](#)]. [PubMed Central: [PMC7202265](#)].
26. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J Endocrinol Invest*. 2021;**44**(4):765–71. doi: [10.1007/s40618-020-01370-x](#). [PubMed: [32772324](#)]. [PubMed Central: [PMC7415009](#)].
27. Ribeiro H, Santana KVS, Oliver SL, Rondo PHC, Mendes MM, Charlton K, et al. Does Vitamin D play a role in the management of Covid-19 in Brazil? *Rev Saude Publica*. 2020;**54**:53. doi: [10.11606/s1518-8787.2020054002545](#). [PubMed: [32491112](#)]. [PubMed Central: [PMC7244235](#)].
28. Mitchell F. Vitamin-D and COVID-19: do deficient risk a poorer outcome? *Lancet Diabetes Endocrinol*. 2020;**8**(7):570. doi: [10.1016/S2213-8587\(20\)30183-2](#). [PubMed: [32445630](#)]. [PubMed Central: [PMC7239633](#)].
29. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab Syndr*. 2020;**14**(4):561–5. doi: [10.1016/j.dsx.2020.04.050](#). [PubMed: [32413819](#)]. [PubMed Central: [PMC7204679](#)].
30. Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Van den Abbeele K, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. *Postgrad Med J*. 2021;**97**(1149):442–7. doi: [10.1136/postgradmedj-2020-138712](#). [PubMed: [32855214](#)]. [PubMed Central: [PMC7456620](#)].
31. Moradzadeh K, Larijani B, Keshkar A, Hossein Nezhad A, Rajabian R, Nabipour I, et al. [Normal values of Vitamin D and prevalence of Vitamin D deficiency among Iranian population]. *Sci J Kurdistan Univ Med Sci*. 2006;**10**(4):22–42. Persian.
32. Sadinia A, Larijani B, Jalalinia S, Farzadfar F, Keshkar AA, Rezaei E, et al. [Prevalence of vitamin D deficiency in Iranian society of Islamic Republic of Iran from 1990 to 2010]. *Iran Diabetes Metab*. 2013;**12**(6):574–84. Persian.
33. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;**356**: i6583. doi: [10.1136/bmj.i6583](#). [PubMed: [28202713](#)]. [PubMed Central: [PMC5310969](#)].
34. Dancer RC, Parekh D, Lax S, D'Souza V, Zheng S, Bassford CR, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). *Thorax*. 2015;**70**(7):617–24. doi: [10.1136/thoraxjnl-2014-206680](#). [PubMed: [25903964](#)]. [PubMed Central: [PMC4484044](#)].
35. Vankadari N, Wilce JA. Emerging Wuhan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. *Emerg Microbes Infect*. 2020;**9**(1):601–4. doi: [10.1080/22221751.2020.1739565](#). [PubMed: [32178593](#)]. [PubMed Central: [PMC7103712](#)].
36. Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections. *Front Microbiol*. 2019;**10**:569. doi: [10.3389/fmicb.2019.00569](#). [PubMed: [30984127](#)]. [PubMed Central: [PMC6448012](#)].
37. Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, et al. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. *Osteoporos Int*. 2009;**20**(11):1881–7. doi: [10.1007/s00198-009-0890-5](#). [PubMed: [19300892](#)].
38. Choudhary N, Gupta P. Vitamin D supplementation for severe pneumonia—a randomized controlled trial. *Indian Pediatr*. 2012;**49**(6):449–54. doi: [10.1007/s13312-012-0073-x](#). [PubMed: [21992858](#)].
39. Zosky GR, Berry LJ, Elliot JG, James AL, Gorman S, Hart PH. Vitamin D deficiency causes deficits in lung function and alters lung structure. *Am J Respir Crit Care Med*. 2011;**183**(10):1336–43. doi: [10.1164/rccm.201010-1596OC](#). [PubMed: [21297070](#)].
40. Brenner H, Holleczer B, Schottker B. Vitamin D Insufficiency and Deficiency and Mortality from Respiratory Diseases in a Cohort of Older Adults: Potential for Limiting the Death Toll during and beyond the COVID-19 Pandemic? *Nutrients*. 2020;**12**(8):2488. doi: [10.3390/nu12082488](#). [PubMed: [32824839](#)]. [PubMed Central: [PMC7468980](#)].
41. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolo A, Lucchini R, et al. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. *Nutrients*. 2020;**12**(5):1359. doi: [10.3390/nu12051359](#). [PubMed: [32397511](#)]. [PubMed Central: [PMC7285131](#)].
42. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. *Clin Endocrinol (Oxf)*. 2020;**93**(4):508–11. doi: [10.1111/cen.14276](#). [PubMed: [32621392](#)]. [PubMed Central: [PMC7361912](#)].